Media Thread, page-10708

'The buck stops with the exec chair'.

Well yes, but that phrase just becomes a cliché when used willy-nilly. You'd probably blame PH meteorite hit our manufacturing facility.

Imugene has consistently added complementary and impressive products/platforms to it's pipeline. It has produced great clinical results to-date with more on the horizon. Milestones get met, which is more than can be said more most biotechs.

Then people critisise the capital management. Even I was caught by surprise by some past CRs (better than word getting out beforehand). However, in hindsight they were great decisions, taking the opportunity to build a warchest, something I wish some of my other biotechs did during the highs.

It's not PHs fault the SP ran so hard up to 60c. And he's got other companies which require cash also, so not surprise or complaints from me when he chose to sell a small portion of his IMU after such a massive run.

Lol 'send a message to the BoD that we expect better'? Cute.

Keep up the awesome work PH, LC and team Imugene.